Literature DB >> 22227451

Use of viral vectors to create animal models for Parkinson's disease.

Karin Löw1, Patrick Aebischer.   

Abstract

Parkinson's disease is a neurodegenerative disorder characterized by the progressive loss of dopaminergic neurons in the substantia nigra. While sporadic in the majority of cases, PD-linked dominant mutations in the α-synuclein and LRRK-2 genes, and recessive mutations in the parkin, DJ-1 and PINK-1 genes have been identified in PD families in recent years. In this review we describe viral animal models for PD, i.e. models that are based on PD-associated mutations, and have been generated by viral delivery of the respective disease genes to the substantia nigra of rodents and non-human primates. To date, viral PD models comprise α-synuclein and LRRK-2-based overexpression models, as well as models that mimic parkin loss of function by overexpression of the parkin substrates Pael-R, CDCrel-1, p38/JTV or synphilin-1. These viral models provide valuable insights into Parkinson disease mechanisms, help to identify therapeutic targets and may contribute to the development of therapeutic approaches.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22227451     DOI: 10.1016/j.nbd.2011.12.038

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  22 in total

Review 1.  Viral vector-based tools advance knowledge of basal ganglia anatomy and physiology.

Authors:  Rachel J Sizemore; Sonja Seeger-Armbruster; Stephanie M Hughes; Louise C Parr-Brownlie
Journal:  J Neurophysiol       Date:  2016-02-17       Impact factor: 2.714

2.  Treatment with Trehalose Prevents Behavioral and Neurochemical Deficits Produced in an AAV α-Synuclein Rat Model of Parkinson's Disease.

Authors:  Qing He; James B Koprich; Ying Wang; Wen-bo Yu; Bao-guo Xiao; Jonathan M Brotchie; Jian Wang
Journal:  Mol Neurobiol       Date:  2015-05-14       Impact factor: 5.590

Review 3.  Hunting for the function of orphan GPCRs - beyond the search for the endogenous ligand.

Authors:  Raise Ahmad; Stefanie Wojciech; Ralf Jockers
Journal:  Br J Pharmacol       Date:  2014-12-15       Impact factor: 8.739

Review 4.  Non-human primate models of PD to test novel therapies.

Authors:  Marc Morissette; Thérèse Di Paolo
Journal:  J Neural Transm (Vienna)       Date:  2017-04-08       Impact factor: 3.575

5.  Intracerebral lentiviral ABCD1 gene therapy in an early disease onset ALD mouse model.

Authors:  Jie Gong; Yunyun Liu; Tsai-Hua Chung; Liu Xu; Troy C Lund; Lung-Ji Chang
Journal:  Gene Ther       Date:  2022-07-06       Impact factor: 5.250

Review 6.  Chronic MPTP administration regimen in monkeys: a model of dopaminergic and non-dopaminergic cell loss in Parkinson's disease.

Authors:  Gunasingh J Masilamoni; Yoland Smith
Journal:  J Neural Transm (Vienna)       Date:  2017-08-31       Impact factor: 3.575

7.  Gene Therapy Models of Alzheimer's Disease and Other Dementias.

Authors:  Benjamin Combs; Andrew Kneynsberg; Nicholas M Kanaan
Journal:  Methods Mol Biol       Date:  2016

Review 8.  α-Synuclein elevation in human neurodegenerative diseases: experimental, pathogenetic, and therapeutic implications.

Authors:  Ayse Ulusoy; Donato A Di Monte
Journal:  Mol Neurobiol       Date:  2012-09-04       Impact factor: 5.590

9.  Stereotaxic Intracranial Delivery of Chemicals, Proteins or Viral Vectors to Study Parkinson's Disease.

Authors:  Natalie Landeck; Melissa Conti Mazza; Megan Duffy; Christopher Bishop; Caryl E Sortwell; Mark R Cookson
Journal:  J Vis Exp       Date:  2021-02-18       Impact factor: 1.355

Review 10.  p38 MAPK and PI3K/AKT Signalling Cascades inParkinson's Disease.

Authors:  Saurabh Kumar Jha; Niraj Kumar Jha; Rohan Kar; Rashmi K Ambasta; Pravir Kumar
Journal:  Int J Mol Cell Med       Date:  2015
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.